Aprepitant

Details

Files

Generic Name:

Aprepitant

Project Status:

Complete

Therapeutic Area:

Nausea and Vomiting, Chemotherapy induced

Manufacturer:

Merck Frosst Canada Ltd.

Brand Name:

Emend

Project Line:

Reimbursement Review

Project Number:

SR0109-000

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Nausea and Vomiting, Chemotherapy induced

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

February 20, 2008

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Summary of CEDAC Discussion View PDF

Overview of CDR Reports View PDF

Plain Language Recommendation View PDF

Last Updated : August 29, 2007